Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09BOH
|
|||
Former ID |
DIB006454
|
|||
Drug Name |
Verubulin
|
|||
Synonyms |
Azixa; Verubulin hydrochloride; EP-128495; MPC-6827; Apoptosis inducer (cancer), Myriad; Caspase inducer (cancer), Myriad; Cell cycle arrest inducer (cancer), Myriad; Tubulin inhibitor (cancer), Myriad
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Brain metastases [ICD-11: 2D50; ICD-10: C79.3; ICD-9: 198.3] | Phase 2 | [1] | |
Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 2 | [2] | ||
Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1], [3] | ||
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [4] | ||
Company |
Maxim Pharmaceuticals Inc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H17N3O
|
|||
Canonical SMILES |
CC1=NC2=CC=CC=C2C(=N1)N(C)C3=CC=C(C=C3)OC
|
|||
InChI |
1S/C17H17N3O/c1-12-18-16-7-5-4-6-15(16)17(19-12)20(2)13-8-10-14(21-3)11-9-13/h4-11H,1-3H3
|
|||
InChIKey |
SNHCRNMVYDHVDT-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 827031-83-4
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin beta (TUBB) | Target Info | Modulator | [5] |
KEGG Pathway | Phagosome | |||
Gap junction | ||||
Pathogenic Escherichia coli infection | ||||
NetPath Pathway | FSH Signaling Pathway | |||
TCR Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Huntington disease | ||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
Loss of Nlp from mitotic centrosomes | ||||
Recruitment of mitotic centrosome proteins and complexes | ||||
Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
Anchoring of the basal body to the plasma membrane | ||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
Pathogenic Escherichia coli infection | ||||
Mitotic G2-G2/M phases |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 4 | ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health. | |||
REF 5 | Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.